{"preliminary_commentary":{"by_channel":{"x_thread":15,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04680442\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["trastuzumab"],["pertuzumab"],["trastuzumab emtansine"]],"indication":"breast cancer with overt left ventricular dysfunction","name":"SCHOLAR-2","nct_id":"NCT04680442","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=scholar-2-nct04680442. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SCHOLAR-2","arms":[{"description":"Recommendations for continuing or holding trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) for the control group are guided by an adaptation of the 2008 Canadian recommendations.","label":"Control Group","type":"ACTIVE_COMPARATOR"},{"description":"The intervention group will continue to receive trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) in the setting of asymptomatic decline in LVEF up to an LVEF of 40% as outlined in the criteria listed in Table 3. For reasons of practicality, in the intervention group, the first dose of trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) after randomization can be administered up to 3 weeks late. This will allow time for the participant to be reviewed by a cardiologist and to receive ACE-I/angiotensin receptor blocker and/or beta-blocker, and for dose titration.","label":"Intervention Group","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-06-30","type":"ESTIMATED"},"conditions":["Breast Cancer","Heart Failure"],"enrollment":{"count":130,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Trastuzumab","otherNames":["Herceptin, Herzuma, Ogivri, Trazimera, Kanjinti"],"type":"DRUG"},{"name":"Pertuzumab","otherNames":["Perjeta"],"type":"DRUG"},{"name":"Trastuzumab emtansine","otherNames":["Kadcyla,"],"type":"DRUG"}],"last_update":"2025-04-06","lead_sponsor":"Population Health Research Institute","official_title":"Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction: A Randomized, Controlled Trial","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"primary efficacy outcome","timeFrame":"one year"},{"measure":"co-primary safety outcomes","timeFrame":"one year"}],"references":[],"start_date":{"date":"2021-07-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","url":"https://clinicaltrials.gov/study/NCT04680442"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/scholar-2-nct04680442"}